ClinicalTrialsFinder

Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) Clinical Trials in Barcelona

1 recruitingBarcelona, Spain

Showing 1–1 of 1 trials

Recruiting
Phase 3

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

Myelodysplastic Syndromes (MDS)Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)
Institut de Recherches Internationales Servier48 enrolled62 locationsNCT06465953